# A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment

> **NCT01448707** · PHASE3 · COMPLETED · sponsor: **Janssen-Cilag International NV** · enrollment: 274 (actual)

## Conditions studied

- Human Immunodeficiency Virus (HIV) Infections
- Acquired Immunodeficiency Syndrome (AIDS) Virus

## Interventions

- **DRUG:** Darunavir
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT01448707
- **Lead sponsor:** Janssen-Cilag International NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-15
- **Primary completion:** 2014-06-11
- **Final completion:** 2015-03-18
- **Target enrollment:** 274 (ACTUAL)
- **Last updated:** 2017-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01448707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01448707, "A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01448707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*